Gynecologic Cancer Treatment Center
Diseases Treated
Ovarian Cancer
Clinical trials for ovarian cancer
If you're interested in a clinical trial, please contact one of our Gyn Oncology Research Nurses:
Julie Lee, RN (617) 632-4975
Christin Whalen (617) 582-7738
For newly diagnosed patients
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy after Carboplatin, Paclitaxel and Avastin Induction Therapy (CTA) for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary
This study is for women with newly diagnosed ovarian cancer, peritoneal cancer, fallopian tube cancer or papillary serous cancer of the endometrium, stage III or IV, who will receive intravenous carboplatin and taxol for their first cycle of chemotherapy after surgery and cycles 2 through 6 consist of carboplatin/taxol and bevacizumab (avastin). Following the completion of chemotherapy, patients will undergo 2nd look surgery and then be randomized to either avastin alone (every three weeks) or the combination of avastin (every three weeks) plus erlotinib. The purpose of this study is to examine how long the cancer stays in remission.
For patients with recurrence of ovarian cancer
A Phase II, open-label, randomized, comparative, international multicenter study to compare the safety and efficacy of two different doses of AZD2281 given orally twice daily versus intravenous liposomal doxorubicin given monthly, in patients with advanced BRCA1- or BRCA2-associated ovarian cancer, who have failed previous platinum-based chemotherapy
AZD2281 is an oral PARP inhibitor that has demonstrated anti-cancer activity in women with recurrent ovarian cancer who also have known germline BRCA1 or BRCA2 mutations. PARP inhibitors are drugs that inhibit an enzyme called PARP that takes over the repair of DNA when the BRCA protein isn't present or isn't working. If DNA repair is inhibited in a cancer cell, that cell will die. This study is comparing three arms: two different doses of the PARP inhibitor and the drug called liposomal doxorubicin (or doxil).
Eligibility: Women must have recurrent ovarian cancer with measurable cancer on a CT or MRI scan, patients must have a known BRCA-1 or BRCA-2 germline mutation, no prior use of doxorubicin (adriamycin) unless at least five years ago and with a total dose of <240 mg/m2, no history of seizures, and no prior history of active or treated cancers within the past five years except in situ carcinoma of the cervix uteri, non-melanoma skin lesions, or endometrial cancer stage IA, grade I. Patients with a history of breast cancer who received definitive treatment more than five years ago before screening can participate even if they received prior adjuvant treatment during the five years prior to screening.
Protocol 05-020: PTK787 Plus Docetaxel for Recurrent Mullerian Malignancies
This is a Phase II study to measure the effectiveness of oral PTK787, a drug that blocks angiogenesis, and docetaxel (taxotere), given weekly intravenously. Another aspect of this study is to test the effect of this drug combination on special MRI scans, called DC-MRI scans.
AZD2171 in Patients with Early, Low-Volume Recurrent Ovarian Epithelial, Primary Peritoneal Serous, or Fallopian Tube Cancer - Ovarian Cancer
AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Learn more
Oxaliplatin, Gemcitabine, and Bevacizumab in Women with Recurrent Mullerian Carcinoma - Ovarian Cancer
This clinical trial is for people who have ovarian cancer, cancer of the tissue lining of the abdomen, or cancer of the fallopian tubes that has recurred after prior treatment. The purpose of this trial is to begin to collect information and try to learn whether or not this drug combination works in treating patients with ovarian cancer, cancer of the tissue lining of the abdomen, or cancer of the fallopian tubes. We will also collect more information about the safety and side effects of this combination of drugs. Learn more
E7389 in Patients with Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer - Ovarian Cancer
Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. This phase II trial is studying how well E7389 works in treating patients with recurrent ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Learn more
Catumaxomab Administered Intraperitoneally in Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
This study tests a novel immunologic drug called Catumaxomab that administered intraperitoneally (IP) and is being tested to see how well it treats ascites (fluid in the abdomen caused by the cancer).
GM-CSF in Women with Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma - Ovarian Cancer
This clinical trial is for women diagnosed with recurrent ovarian cancer, cancer of the tissue lining your abdomen, or cancer of the fallopian tubes, but you have not experienced any symptoms yet. The purpose of this trial is to figure out what effects (good or bad) the investigational drug GM-CSF has on participants. This is a Phase II clinical trial. This trial will evaluate how effective and how safe the investigational drug GM-CSF as treating this type of cancer. Learn more
More ovarian cancer clinical trials
Please continue to check this page for updates. New clinical trials for ovarian cancer are added all the time.
Entering a Clinical Trial; Is it Right for You?
